Introduction
The outcome of patients with acute lymphoblastic leukemia (ALL) has improved with intensification of therapy. Complete remission (CR) can now be achieved in the majority of adults with ALL, but only 30-40% are cured, the proportion varying according to well-described clinical and biological risk factors [1] [2] [3] [4] [5] [6] [7] [8] [9] . In recent years, two main consolidation strategies have been used to try and improve outcome: intensive chemotherapy programs, reserving allogeneic stem cell transplantation (SCT) for patients with Philadelphia chromosome (Ph)-positive ALL (Ph + ALL), or allogeneic SCT for all patients in 1st CR with a sibling donor. Whilst some studies have shown equivalent outcomes for the two latter approaches [10, 11] , others have demonstrated better results in specific subgroups of patients receiving an allograft [12] [13] [14] . The cooperative MRC/ ECOG trial showed better overall survival with SCT in patients with standard-risk ALL but failed to prove superiority for SCT in the high-risk category, due to a high treatment-related mortality (36% at 2 years) [13] .
In view of the impressive results achieved in Germany using an intensive, sequential chemotherapy protocol given over 12 months [15] , in September 2000, a modified version of the German Multicenter Study Group for Adult ALL GMALL 06/99 protocol was adopted at St. Bartholomew's Hospital. The aim of this analysis was to evaluate the outcome of patients receiving this regimen, which includes the use of gram doses of cyclophosphamide and methotrexate. The original protocol was modified as follows: standard-dose cytarabine was given subcutaneously instead of intravenously (equivalence having been demonstrated in terms of the blood levels achieved [16] ), obviating the need for hospital attendance, let alone admission. Furthermore, gram doses of cyclophosphamide and methotrexate were given in the Day Unit, rather than patients being admitted. Gram-dose methotrexate was followed by folinic acid: 30 mg orally, every 6 h, for a total of six doses.
Design and methods

Patients
Between September 2000 and June 2007, 53 consecutive, newly diagnosed patients aged between 15 and 70 years with Ph-negative B-or T-lineage ALL (excluding mature B-ALL), received the modified "GMALL" protocol. Signed, informed consent for treatment was required. The diagnosis was based on morphological examination of bone marrow (BM) and peripheral blood and on flow cytometric immunophenotyping. Standard cytogenetic analysis was performed to complete the diagnostic profile.
Patients with the following risk factors: pro-B-ALL, pre-B-ALL with WBC ≥30×10 9 /L, early or mature T or thymic T-ALL with WBC ≥100×10 9 /L, and ALL with an MLL rearrangement, were defined as being at "high risk" (HR) for recurrence [4] . All other patients were designated "standard risk" (SR). Clinical characteristics are shown in Table 1 . Based on risk factors, 24 patients (45%) had "HR" ALL, and 29 (55%), "SR" disease.
Treatment
Treatment strategy Treatment continued for 12 months. Following initial admission for diagnosis and administration of remission induction therapy, once the neutrophil count had recovered to 0.5×10 9 /L, patients were treated as much as possible on an out-patient basis, attending the Hemato-Oncology Day Unit at SBH, twice or thrice weekly.
The standard doses of cytarabine were administered by the patient, a trained relative, or by a district nurse. Methotrexate (1.5 g/m 2 ) followed by oral leucovorin rescue and cyclophosphamide (1 g/m 2 ) were given on the Day Unit, each over a period of 1 h, with stringent attention to hydration. Thus, unless there was a specific contraindication, patients who lived within a 45-min drive from the hospital were able to be at home for a substantial proportion of the 12 months. They were of course always admitted immediately in the event of a problem, admission for intravenous antibiotics being mandatory for symptoms and/ or signs of sepsis in the presence of neutropenia (defined as neutrophils <1.0×10 9 /L). In contradistinction to the original protocol, it was decided a priori that no patients would electively have an allograft in 1st remission, (those with Ph+ve ALL being treated according to a different protocol). The treatment strategy was also not based on evaluation of "minimal residual disease."
Treatment details are shown in Fig. 1 . Remission induction chemotherapy consisted of two blocks, the first comprising: dexamethasone, vincristine, daunorubicin, and PEG-asparaginase given over 3 weeks, followed by a second 3-week cycle comprising cyclophosphamide, cytar- [7] b An IgH rearrangement was demonstrated by "FISH," but there was no MYC rearrangement abine, and 6-mercaptopurine (6-MP). Consolidation therapy consisted of six cycles, four of which included gram doses of methotrexate, and one, high-dose cytarabine, over a period of 44 weeks, with two re-induction blocks, at weeks 22 and 24. G-CSF was given throughout to maintain the neutrophil count at ≥1×10 9 /L in order to reduce treatment delays and the risk of infection. Central nervous system (CNS) prophylaxis was given in both T-and Blineage ALL and comprised four intrathecal (IT) injections of methotrexate and "5 triple IT" injections, followed by cranial irradiation (18 Gy) on completion of chemotherapy (weeks 52-56). A standard maintenance therapy with 6-mercaptopurine and methotrexate for 2 years was administered only in patients with B-lineage ALL. Patients with T-ALL did not receive any maintenance.
Response criteria A bone marrow aspiration was performed on day 24. At this point, the blood count invariably showed profound cytopenia, and the bone marrow was virtually always hypocellular with no leukemic blast cells. On recovery of the count (to levels compatible with the definition of CR), the bone marrow aspiration was repeated (to document CR), and the next cycle of treatment started. In patients in whom the bone marrow at day 24 showed >30% blasts, the second induction cycle was given irrespective of the blood count, if the patient was otherwise well enough to continue treatment.
Complete remission was defined as a morphologically normal marrow with less than 5% blasts, when the Hb >10 g/ L, neutrophils >1×10 9 /L, and platelets >100×10 9 /L. Refractory ALL was defined as persistent leukemia following two cycles of induction chemotherapy. Early death was defined as death during induction before treatment response had been assessed and relapse as recurrence of disease following achievement of CR. Relapses were further classified as isolated to BM (>5% blasts), isolated to the CNS, or "combined" (recurrence in BM and CNS concurrently).
Statistical analysis
Overall Survival (OS) was measured from the date of diagnosis to the date of death or last follow-up. Disease-free survival (DFS) was calculated from the date of CR to the date of relapse or death in CR from any cause and was censored at last follow-up. Remission Duration was calculated from the date of CR to the date of relapse or II  I  II  I  II  III  IV  V last follow-up. Actuarial survival analysis was performed according to the method described by Kaplan and Meier, and the curves were compared by the log-rank test. Differences in response rate across patient subgroups were compared by the χ 2 statistic.
Results
Response to treatment
CR was achieved in 47/53 patients (89%), with no significant difference in CR rate between B-and T-ALL. There were three early deaths from infection, and three patients had refractory disease. Age ≥35 years was the only significant factor associated with a lower probability of achieving CR (p=0.004). No statistically significant difference in CR rate was observed between SR and HR groups (27/29 vs. 20/24, respectively, p=0.39). CR was achieved in all four patients with an MLL rearrangement.
Survival
At a median follow-up of 5.5 years (range, 2.5-8.5), 25/53 patients are alive (47%), 23 (43%) in 1st CR. Three patients died after >4 years in CR, two from secondary myelodysplasia and one who tragically took his own life. The estimated 5-year OS was 50% and did not differ significantly between patients with SR ALL (52%) and HR ALL (48%) risk (p=0.4) (Fig. 2) . There was likewise no statistically significant difference in OS or DFS between patients who presented with unfavorable cytogenetics and those with favorable/intermediate cytogenetic abnormalities (data not shown). Six of the 21 patients who developed recurrent disease (see below) are alive.
Remission duration
Recurrence occurred in 21/47 patients overall, 1 month to 6 years following achievement of CR. The median remission duration was 6 years (range, 0.1-8 years) (Fig. 3) . Fourteen patients relapsed in BM alone (at 0.5-6 years), four had an isolated CNS relapse (at 0.3-1.4 years), and three developed recurrent leukemia concurrently in the BM and CNS. Three of the seven patients who developed recurrent leukemia in the CNS had T-ALL. At 1st recurrence, 15/21 patients were retreated with curative intent, 2nd CR being achieved in 8/ 15. Four went on to receive an allogeneic SCT, but only one of the latter is alive (at 7.3 years). Two of the four patients with an MLL rearrangement developed recurrent leukemia; two subsequently died, and two remain well in 1st CR.
The estimated 5-year DFS was 53%, ranging from 57% in SR ALL to 48% in the HR ALL (p=0.5) (Fig. 4) . There was a trend towards better DFS in patients with T-lineage ALL, with an estimated DFS of 60% at 5 years, compared with 50% in B-lineage ALL (p=0.39). Induction and postinduction results are summarized in Table 2 . Thirty four of the 47 patients in whom CR was achieved completed the planned therapy and are thus evaluable for assessment of duration of in-patient stay and number of Day Unit attendances over the 12-month period. Thirteen patients were unable to complete therapy (eight due to unacceptable clinical toxicity and five because of recurrence whilst on treatment). The median total duration of in-patient stay was 10 weeks (range, 6-44), made up of the initial 4 weeks, and subsequent admissions for those parts of the protocol that required the patient to be in hospital and admissions for treatment of neutropenic sepsis. There was no statistically significant difference in duration of in-patient stay between younger (≤30 years) and older patients (>30). The median number of Day Unit attendances was 20 (range, 2-69). (The "outlying" results relate to one patient who remained in hospital for virtually the whole time, 44 weeks, and therefore attended the Day Unit only twice. She had multiple previous and concurrent medical problems, which in turn resulted in numerous complications. The person was therefore unable to complete the planned treatment, unfortunately developed recurrent leukemia, and died).
Discussion
The intensive "GMALL" regimen was modified to enable treatment to be given mainly in the out-patient setting. Doing so did not compromise the results overall, 50% of patients being alive at 5 years. These results are certainly not inferior to those achieved elsewhere [3-6, 12-15, 17] and have been achieved without resource to allogeneic stem cell transplantation in 1st remission. Moreover, they compare favorably with outcomes reported using the same regimen but given predominantly to patients in hospital [15] . Standard-risk factors did not appear to influence outcome, whilst with regard to immunophenotype, relatively good results were achieved in the small group of patients with T-ALL (DFS 60% at 5 years). Amongst the factors that probably contributed to this favorable outcome, particularly in the patients with T-ALL, was the use of "gram doses" of cytarabine and cyclophosphamide, both known to be associated with better outcome in this subgroup [5, 18, 19] . It is somewhat unusual for cyclophosphamide and methotrexate to be given at gram doses in the out-patient setting. In Germany, this protocol usually involves admission to hospital for prolonged periods of time (D. Hoelzer, personal communication). In the patients treated at SBH, the "gram-dose" chemotherapy cycles were well tolerated and were not associated with any treatment-related deaths in CR.
The bone marrow recurrence rate was relatively low (17/ 47, 36%) in a population well balanced between standardand high-risk patients. In contrast, the CNS recurrence rate was quite high (8.5%). The reasons for this are not clear, considering that the systemic chemotherapy included high doses of CNS-penetrating agents. In particular, the administration of high-dose methotrexate over a period of 1 h results in higher serum concentrations than prolonged infusion, with correspondingly higher concentrations in the cerebrospinal fluid. However, the dose of prophylactic cranial irradiation was relatively low, 18 Gy, and the radiotherapy was delayed until completion of 12 months' chemotherapy. This prophylactic schedule was associated with an unacceptably high CNS relapse rate of 30% (3/10) in T-ALL. This could perhaps be improved in this high-risk subset through the use of an earlier cranial irradiation and/ or a greater exposure to systemic high-dose cytarabine or higher methotrexate doses.
In conclusion, this study has confirmed the reproducibility of the GMALL 06/99 protocol [4] modified for outpatient administration in adult patients with ALL and has identified interesting possibilities for simplifying therapy, particularly for patients with standard-risk ALL. It proved possible to administer this intensive protocol largely on an out-patient basis, without compromising patient safety. The potential implications of the findings, for example, the use of subcutaneous cytosine arabinoside, able to be selfadministered or given by a district nurse at home, if widely adopted, would have considerable impact if implemented generally.
